298 related articles for article (PubMed ID: 34561239)
1. Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response.
Shields AM; Faustini SE; Perez-Toledo M; Jossi S; Allen JD; Al-Taei S; Backhouse C; Dunbar LA; Ebanks D; Emmanuel B; Faniyi AA; Garvey M; Grinbergs A; McGinnell G; O'Neill J; Watanabe Y; Crispin M; Wraith DC; Cunningham AF; Drayson MT; Richter AG
BMJ Open Respir Res; 2021 Sep; 8(1):. PubMed ID: 34561239
[TBL] [Abstract][Full Text] [Related]
2. Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response.
Shields AM; Faustini SE; Perez-Toledo M; Jossi S; Allen JD; Al-Taei S; Backhouse C; Dunbar L; Ebanks D; Emmanuel B; Faniyi AA; Garvey MI; Grinbergs A; McGinnell G; O'Neill J; Watanabe Y; Crispin M; Wraith DC; Cunningham AF; Drayson MT; Richter AG
medRxiv; 2020 Nov; ():. PubMed ID: 33236029
[TBL] [Abstract][Full Text] [Related]
3. Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients.
Cook AM; Faustini SE; Williams LJ; Cunningham AF; Drayson MT; Shields AM; Kay D; Taylor L; Plant T; Huissoon A; Wallis G; Beck S; Jossi SE; Perez-Toledo M; Newby ML; Allen JD; Crispin M; Harding S; Richter AG
J Immunol Methods; 2021 Jul; 494():113046. PubMed ID: 33775672
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study.
Shields A; Faustini SE; Perez-Toledo M; Jossi S; Aldera E; Allen JD; Al-Taei S; Backhouse C; Bosworth A; Dunbar LA; Ebanks D; Emmanuel B; Garvey M; Gray J; Kidd IM; McGinnell G; McLoughlin DE; Morley G; O'Neill J; Papakonstantinou D; Pickles O; Poxon C; Richter M; Walker EM; Wanigasooriya K; Watanabe Y; Whalley C; Zielinska AE; Crispin M; Wraith DC; Beggs AD; Cunningham AF; Drayson MT; Richter AG
Thorax; 2020 Dec; 75(12):1089-1094. PubMed ID: 32917840
[TBL] [Abstract][Full Text] [Related]
5. Antibody tests for identification of current and past infection with SARS-CoV-2.
Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
[TBL] [Abstract][Full Text] [Related]
6. A Serological Snapshot of COVID-19 Initial Stages in Israel by a 6-Plex Antigen Array.
Fisher M; Levy H; Fatelevich E; Afrimov Y; Ben-Shmuel A; Rosenfeld R; Noy-Porat T; Glinert I; Sittner A; Biber A; Belkin A; Bar-David E; Puni R; Levy I; Mazor O; Weiss S; Mechaly A
Microbiol Spectr; 2021 Oct; 9(2):e0087021. PubMed ID: 34612689
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections.
Huber T; Steininger P; Irrgang P; Korn K; Tenbusch M; Diesch K; Achenbach S; Kremer AE; Werblow M; Vetter M; Bogdan C; Held J
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1983-1997. PubMed ID: 34109500
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19.
Glück V; Grobecker S; Tydykov L; Salzberger B; Glück T; Weidlich T; Bertok M; Gottwald C; Wenzel JJ; Gessner A; Schmidt B; Peterhoff D
Infection; 2021 Aug; 49(4):739-746. PubMed ID: 33689159
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.
Zervou FN; Louie P; Stachel A; Zacharioudakis IM; Ortiz-Mendez Y; Thomas K; Aguero-Rosenfeld ME
J Med Virol; 2021 Sep; 93(9):5409-5415. PubMed ID: 33932299
[TBL] [Abstract][Full Text] [Related]
11. Closing the serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-2 IgA antibodies.
Infantino M; Manfredi M; Grossi V; Lari B; Fabbri S; Benucci M; Fortini A; Damiani A; Mobilia EM; Panciroli M; Pancani S; Pesce G
J Med Virol; 2021 Mar; 93(3):1436-1442. PubMed ID: 32790181
[TBL] [Abstract][Full Text] [Related]
12. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England.
Wells PM; Doores KJ; Couvreur S; Nunez RM; Seow J; Graham C; Acors S; Kouphou N; Neil SJD; Tedder RS; Matos PM; Poulton K; Lista MJ; Dickenson RE; Sertkaya H; Maguire TJA; Scourfield EJ; Bowyer RCE; Hart D; O'Byrne A; Steel KJA; Hemmings O; Rosadas C; McClure MO; Capedevilla-Pujol J; Wolf J; Ourselin S; Brown MA; Malim MH; Spector T; Steves CJ
J Infect; 2020 Dec; 81(6):931-936. PubMed ID: 33068628
[TBL] [Abstract][Full Text] [Related]
13. Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts.
Bortz RH; Florez C; Laudermilch E; Wirchnianski AS; Lasso G; Malonis RJ; Georgiev GI; Vergnolle O; Herrera NG; Morano NC; Campbell ST; Orner EP; Mengotto A; Dieterle ME; Fels JM; Haslwanter D; Jangra RK; Celikgil A; Kimmel D; Lee JH; Mariano MC; Nakouzi A; Quiroz J; Rivera J; Szymczak WA; Tong K; Barnhill J; Forsell MNE; Ahlm C; Stein DT; Pirofski LA; Goldstein DY; Garforth SJ; Almo SC; Daily JP; Prystowsky MB; Faix JD; Fox AS; Weiss LM; Lai JR; Chandran K
mSphere; 2021 Apr; 6(2):. PubMed ID: 33883259
[TBL] [Abstract][Full Text] [Related]
14. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust.
Hodgson D; Colton H; Hornsby H; Brown R; Mckenzie J; Bradley KL; James C; Lindsey BB; Birch S; Marsh L; Wood S; Bayley M; Dickson G; James DC; Nicklin MJH; Sayers JR; Zafred D; Rowland-Jones SL; Kudesia G; Kucharski A; ; Darton TC; de Silva TI; Collini PJ
medRxiv; 2021 Jul; ():. PubMed ID: 34268521
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Seroprevalence in Healthcare Workers of Kaunas Hospitals during the First Wave of the COVID-19 Pandemic.
Pereckaitė L; Dambrauskienė A; Urbonienė D; Sadauskas S; Petrikonis K; Naudžiūnas A; Vitkauskienė A
Medicina (Kaunas); 2021 Feb; 57(2):. PubMed ID: 33562085
[No Abstract] [Full Text] [Related]
17. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers.
Kurano M; Morita Y; Nakano Y; Yokoyama R; Shimura T; Qian C; Xia F; He F; Zheng L; Ohmiya H; Kishi Y; Okada J; Yoshikawa N; Nakajima K; Nagura Y; Okazaki H; Jubishi D; Moriya K; Seto Y; Yasui F; Kohara M; Wakui M; Kawamura T; Kodama T; Yatomi Y
Int Immunopharmacol; 2022 Feb; 103():108491. PubMed ID: 34954559
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Seroprevalence Study in Pediatric Patients and Health Care Workers Using Multiplex Antibody Immunoassays.
Prados de la Torre E; Obando I; Vidal M; de Felipe B; Aguilar R; Izquierdo L; Carolis C; Olbrich P; Capilla-Miranda A; Serra P; Santamaria P; Blanco-Lobo P; Moncunill G; Rodríguez-Ortega MJ; Dobaño C
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146844
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up.
Moncunill G; Mayor A; Santano R; Jiménez A; Vidal M; Tortajada M; Sanz S; Méndez S; Llupià A; Aguilar R; Alonso S; Barrios D; Carolis C; Cisteró P; Chóliz E; Cruz A; Fochs S; Jairoce C; Hecht J; Lamoglia M; Martínez MJ; Moreno J; Mitchell RA; Ortega N; Pey N; Puyol L; Ribes M; Rosell N; Figueroa-Romero A; Sotomayor P; Torres S; Williams S; Barroso S; Vilella A; Trilla A; Varela P; Dobaño C; Garcia-Basteiro AL
J Infect Dis; 2021 Jan; 223(1):62-71. PubMed ID: 33175145
[TBL] [Abstract][Full Text] [Related]
20. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
